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Early Clinical and Radiological 
Experience with a Ceramic Bone 
Graft Substitute in the Treatment 
of Benign and Borderline Bone 
Lesions
Peter Frederik Horstmann  1, Werner Herbert Hettwer1, Nicolai Stefan Kaltoft2 & 
Michael Mørk Petersen1
Substitutes for bone grafts experience increasing popularity, but the need for defect-filling following 
simple curettage of benign bone lesions is controversial. In this study, we wish to objectively report 
the radiological changes following bone defect-filling using a composite ceramic bone graft substitute, 
as well as the clinical results and complications. We evaluated 35 surgically treated benign bone 
lesions with subsequent defect-filling using two variants of a composite ceramic bone graft substitute 
(CERAMENT|BONE VOID FILLER or CERAMENT|G, BONESUPPORT AB, SWEDEN). After one year, a 
normal cortical thickness surrounding the defect was seen in approximately 80% of patients. Inside 
the defect-cavity, an almost complete product-resorption was seen after one year. The most common 
complication was a post-operative inflammatory soft-tissue reaction, seen in 7 patients (20%), which 
resolved without further treatment, although short-term antibiotic treatment was initiated at a 
local hospital in 6 patients, due to suspected wound infection. In summary, cortical thickness most 
commonly normalizes after bone tumor removal and filling of the bone defect using this particular 
composite ceramic bone graft substitute. The ceramic substitute undergoes resorption, which causes 
progressive changes in the radiological appearance inside the bone defect.
How to manage a bone-defect following bone-tumor surgery is controversial, and some authors believe that 
defect-grafting is only rarely required1,2. One of the main reasons for this controversy is the lack of objective 
clinical evidence regarding new-bone formation in bone-defects, and the effect on bone-strength. The evidence is 
obviously lacking due to heavy restrictions on what is possible to measure in humans. Perhaps the most important 
parameter, bone-strength, is virtually impossible to measure objectively. Cortical thickness is therefore typically 
used as a surrogate measure for bone-strength, and various criteria, incorporating cortical thickness, have been 
developed, in order to predict the risk of fracture3,4. Some authors have used the lack of post-operative fractures as 
an indirect measure for bone-strength1,2. Although this is intuitively reasonable, the question remains if cortical 
thickness in fact normalizes. A partially decreased cortical thickness might not cause problems for young and 
healthy individuals, but it could likely pose a problem for older and osteoporotic individuals. We therefore believe 
that efforts should be made to restore cortical, and to some extent cancellous, bone-volume, in order to regain 
and retain bone-strength. In this observational study, we aim to quantify changes in cortical thickness, as well as 
changes in the radiological appearance inside the defect cavity, following bone-defect filling, using a composite 
ceramic bone graft substitute (BGS), in the treatment of patients with bone-tumors and cysts. Further, we wish 
to report the clinical results and complications of this particular BGS. We hypothesize that cortical thickness and 
cavity-healing increases during the first postoperative year after curettage and filling with a commercially availa-
ble BGS in patients suffering from benign or borderline bone lesions.
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Results
We identified 34 patients (M/F = 17/17, mean age = 32 (5–69) years), who were treated for 35 benign (n = 32) 
or borderline bone-lesions (giant cell tumors of bone (n = 2) and chondrosarcoma grade 1 (n = 1)) (Table 1). 
Approximately 3 quarters of the bone-lesions were situated in the lower extremity (27 of 35). The most common 
histo-pathological diagnosis encountered were simple bone-cysts (n = 9), followed by enchondromas (n = 8).
Radiological evaluation of bone healing. Of the 35 bone lesions, 28 met the criteria for the comparative 
radiological evaluation at 12-months. The remaining 7 patients were excluded, due to local recurrence (n = 3) or 
re-operation before the 12-months control (n = 2), or due to missing 12-months x-ray (n = 2). Approximately 
40% (11 of 28) of the defect-cavities showed normal radiological appearance after one year, whereas a normal 
cortical thickness was seen in 79% (22 of 28) of the cases (Table 2). In 13 patients, with a pre-operative reduction 
in cortical thickness, an improved thickness was achieved in 10 cases (77%) (Fig. 1). Only one patient, with a 
progressive lesion, had a diminished cortical thickness after one year. In 5 patients, all below 18 years of age, 
the ratio of normal-appearing bone inside the defect-cavity after one year improved in comparison to the ratio 
of post-operative defect-filling (Fig. 2, upper row). Conversely, the ratio of normal-appearing bone inside the 
defect-cavity was lower than the ratio of post-operative defect-filling in 12 patients.
Of the 35 bone lesions, 31 met the criteria for the modified Neer’s classification, which includes local recur-
rences (n = 3) (Table 3). Evaluation of the 1-year radiographs according to the modified Neer’s classification 
deemed: 11 patients in group I (Complete healing); 9 in patients in group II (Partial healing), 8 patients in group 
III (Persistent lesion), and 3 in group IV (Recurrent lesion). It should be noted that 6 of the 8 patients in group III 
were deemed to this category, due to incomplete defect fill, despite a normal, or close to normal, cortical thick-
ness, while only 2 patients were in this category, due to significantly reduced cortical thickness.
Local recurrence and reoperations. Four patients had local recurrence: 2 giant cell tumors, after 3 and 
7 months (pathology verified); and 2 aneurysmal bone-cysts, after 3 months and 16 months (progression on 
x-ray) (Table 4). The giant cell tumors were treated by re-curettage, while the aneurysmal bone-cysts were treated 
No. of patients/lesions 34/35
Female/Male 17/17
Age (range) 32 (5–69) years










  Aneurysmal bone cyst 3
  Giant cell tumor of bone 2
  Non-ossifying fibroma 1
  Giant cell granuloma 1
  Chondrosarcoma grade I 1
  Non-specific reactive lesion 4
Table 1. Patient and bone lesion characteristics. *Children/Adults: 5/4.
Radiological appearance Post-operatively After 1 year Grade development
Cavity fill >90% 13a 11b Improved 5
Cavity fill 50–90% 12a 8b Same 11
Cavity fill 10–50% 3a 5b Reduced 12
Cavity fill <10% 0a 4b
Cortex thickness >90%c 15 22 Improved 10
Cortex thickness 50–90%c 6 3 Same 17
Cortex thickness 10–50%c 6 2 Reduced 1
Cortex thickness <10%c 1 1
Table 2. Comparative radiological evaluation. aCavity filling of bone graft substitute. bCavity filling of bone 
with normal radiographic appearance. cCortical thickness compared to surrounding normal cortex.
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percutaneously by injection of a sclerosing agent (sclerotherapy). Two patients received re-curettage due to sus-
pected recurrence of a lesion with a non-specific primary diagnose, but neither recurrence nor a more precise 
diagnose was confirmed. Three patients received a second grafting procedure in order to further increase bone 
stock, although no progression or recurrence was seen: two children with large bone cysts in the pelvis and proxi-
mal femur received re-injection of CERAMENT|BONE VOID FILLER: one filled percutaneously (pelvis) after 13 
months, and one filled at the same time as a scheduled plate removal after 20 months; and one adult was treated 
with curettage and bone grafting after 10 months, due to a large remaining cavity just beneath the knee-joint 
(Fig. 2, lower row). One patient with an intra-osseous ganglion received re-curettage and bone-grafting after 14 
months, due to persistent pain from the ankle joint, which was expected to resolve by complete cavity-filling, 
despite a normal cortical thickness.
In case of a suspected local recurrence (n = 6), the indication for reoperation was decided on a multidisci-
plinary team conference. Choice of defect-filling in the following re-operation, as well as indication for revision 
surgery in the remaining 4 cases, was based on clinical judgement of the attending physician.
Postoperative complications and radiological irregularities. Minor complications occurred in 
9 patients. One patient had a suspected post-operative non-displaced fracture of the medial malleolus, which 
was noticed retrospectively during a radiographic conference 2 months later. No intervention was needed. One 
patient had postoperative wound secretion for 10 days, which resolved by its own without further treatment or 
complications. Seven patients developed postoperative soft-tissue inflammation around the surgical site, which 
resolved without additional signs of wound-infection: such as wound secretion or pus. Despite this, 6 patients 
were prescribed prophylactic antibiotics, typically by their local emergency department or general practitioner. 
Of the 7 patients with an inflammatory reaction, 6 patients had a lesion in close relation to the knee, and one 
had a lesion in the foot. One of the patients, with an inflammatory reaction, was suspected of postoperative 
compartment-syndrome in the anterior and lateral muscle compartments of the lower leg, after defect-filling of 
the proximal fibula. Symptoms were pain, swelling, and impaired dorsi-flexion in the ankle joint and the patient 
Figure 1. Upper row: Simple cyst of the proximal humerus treated by curettage and defect-filling using 
CERAMENT|BONE VOID FILLER. (A,B) Pre- and post-operative x-rays showing decreased cortical 
thickness as well an isolated chamber in the distal part of the affected bone (arrow), which is not accessed or 
filled during the operation. (C–E) X-rays taken after 6 weeks, 3 and 6 months showing increasing product 
resorption and cortical thickening. (F) X-ray taken after 12 months showing normal cortical thickness in the 
main part of the cyst, and reduced cortical thickness in the non-treated distal chamber as a sign of possible 
local recurrence. Lower row: Aneurysmal bone cyst of the distal tibia treated by curettage and defect-filling 
using CERAMENT|BONE VOID FILLER. (G,H) Pre- and post-operative x-rays showing decreased anterior 
cortical thickness and complete defect filling. (I–L) X-rays taken after 6 weeks and 3, 6, and 12 months showing 
increasing product resorption and cortical thickening. Note the increasing distance between the growth-plate and 
the distal aspect of the cyst.
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received a fasciotomy, revealing intact muscle-tissue. After a sclerotherapy-injection 3 months later, in the same 
bone defect, the patient developed a transient post-injection peroneal palsy. The apparent proximity between 
the tumor and the peroneal nerve was suspected to have caused the impaired dorsi-flexion in relation to the 
primary operation as well, making the compartment-syndrome diagnosis less likely. No patients experienced a 
deep infection.
In 9 patients, an irregularity was noticed on the follow-up x-rays. In 7 of 9 patients, a small amount of bone- 
graft substitute was seen in the soft-tissue on the x-ray taken immediately postoperatively. In all 7 cases, the 
bone-graft substitute resorbed within 3 to 6 months. Only 1 of the 7 cases developed an inflammatory reac-
tion. One of 9 patients, with a bone-defect in the femur requiring a large bone window, developed a progressive 
leak of the bone-graft substitute into the soft-tissue, despite no leakage was seen on the postoperative x-rays 
(Fig. 3). The leak was non-symptomatic and resolved between 6 and 12 months postoperatively. One of 9 patients 
Figure 2. Upper row: Enchondroma of a 12-year old girl treated by curettage and defect-filling using 
CERAMENT|BONE VOID FILLER. (A,B) Pre-operative MRI and x-ray showing decreased cortical thickness. 
(C) X-ray taken post-operatively showing near complete defect-filling. (D,E) X-rays taken after 6 weeks, and 
6 months showing increasing product resorption and cortical thickening. (F) X-ray taken after 12 months 
showing normal cortical thickness and signs of cavity-remodeling. Lower row: Large bone infarction of the 
proximal tibia treated by curettage and defect-filling using CERAMENT|BONE VOID FILLER. (G,H) Pre- and 
post-operative x-rays showing decreased cavity radiolucency and near complete defect-filling. (I–K) X-rays 
taken after 6 weeks, and 3 and 6 months showing increasing product resorption and persistent reduced defect-
radiolucency. (L) 6-months CT-scan showing a peripheral reactive zone in the defect and a seemingly empty 
cavity.
Score Classification Description
I Complete Healing Complete or almost complete* filling of the initial lesion with radiological evidence of new bone formation
II Partial Healing Incomplete healing and/or graft resorption in an area(s) less than 50% of the initial lesion with enough cortical thickness to prevent fracture
III Persistent Lesion Graft resorption or persistent radiolucent area (s) greater than 50% of the initial lesion and/or with a thin cortical rim potentially at risk for fracture
IV Recurrent lesion Progressive lesion reappeared in a previously obliterated area or a residual radiolucent area verified by biopsy
Table 3. Modified Neer classification of radiological evaluation of bone defect healing. *with or without small 
non-progressive radiolucent area(s) less than 1 cm in size.
www.nature.com/scientificreports/
5SCienTifiC REPORTS |  (2018) 8:15384  | DOI:10.1038/s41598-018-33736-w
developed a calcification in the trochanteric bursa after treatment of a bone defect in the proximal femur. No leak 
of bone-graft substitute was seen in this patient.
Discussion
In this study, we have quantified changes in cortical thickness and radiological bone cavity appearance, following 
tumor removal and bone defect filling using a composite ceramic bone graft substitute, in 35 benign bone-tumors 
or cysts. We found that cortical bone responded well to treatment. After one year, cortical bone thickness normal-
ized, or remained normal, in 80% of cases. Inside the bone cavity, normal radiographic appearance was achieved 
in 40% of cases after one year. Only in patients, below the age of 18, did the degree of normal radiographic appear-
ance, inside bone cavity, improve beyond the degree of postoperative defect-filling.
# Histology Bone Indication Time-point* Re-operation
1 GCTa Distal tibia Local recurrence 3 m Curettage
2 GCTa Proximal femur Local recurrence 7 m Curettage
3 ABCb Proximal fibula Local recurrence 3 m Sclerotherapy
4 ABCb Distal tibia Local recurrence 16 m Sclerotherapy
5 Non-specific Proximal femur Suspected LRe 21 m Curettage
6 Non-specific Patella Suspected LRe 11 m Curettage
7 SCc Proximal femur Plate removal 20 m Inj CERAMENT
8 SCc Pelvis Pain/Bone stock 13 m Inj CERAMENT
9 Bone infarction Proximal tibia Bone stock 10 m Curettage
10 IOGd Distal tibia Pain 14 m Curettage
Table 4. Re-operations. *Time from primary operation (months). aGCT: Giant cell tumor. bABC: Aneurysmal 
bone cyst. cSC: Simple cyst. dIOG: Intraosseous ganglion. eLR: local recurrence.
Figure 3. A patient treated by curettage and defect filling, using a combination of CERAMENT|G (20mL) and 
CERAMENT|BONE VOID FILLER (36mL) via an extended cortical window, for a large enchondroma in the 
left distal femur. (A) Pre-operative MRI-scan. (B) Post-operative x-ray without product-leakage (C,D) X-rays 
after 6 weeks and 12 weeks showing soft-tissue leakage. (E) X-ray after 6 months showing almost complete 
resorption of soft-tissue leakage. Outline of the bone window is clearly visible. (F) X-ray after 12 months 
showing complete resorption of the soft-tissue leakage, blurring of the bone window, and thickening of the 
posterior and lateral cortex.
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Prediction of risk factors for a pathological fracture has been studied mostly in patients with metastatic bone 
disease5,6. Although different criteria have been used, all studies agree that cortical impairment increases the risk 
of fracture. Direct translation of these results to benign bone lesions should be done carefully, but in a study of 155 
benign bone cysts, similar results were shown7. The positive effect on cortical thickness, seen in our study, would 
therefore most likely have improved bone strength.
In terms of translating the radiological cavity-appearance into trabecular bone healing, the results should be 
interpreted cautiously. In some parts of the skeleton, up to 50% of the bone mass needs to be destroyed by an oste-
olytic lesion, before it is detectable on plain x-ray8. The ratio between cortical and trabecular bone varies greatly, 
depending on the bone-region, from around 50:50 in metaphyses of long bones down to 95:5 in diaphyseal bone9. 
This means that evaluation of trabecular bone formation is virtually impossible on plain radiographs, as most 
changes will be invisible due to overlapping cortical bone, especially in diaphyseal bone.
Kaczmarczyk et al. evaluated the same bone graft substitute, as used in our study, for percutaneous treatment 
of bone defects10. They found complete healing (grade 1), according to a modified Neer’s classification, in 11 of 
14 patients, despite incomplete post-operative filling in most cases. Possible explanations for the higher rating 
compared to our study include: difference in mean age (13 years compared to 32 years in our study), composition 
of histology (8 of 14 were simple cysts in the proximal humerus), and tumor localization. Low age was associated 
with an improved radiological cavity-appearance in our study, and the typical localization of proximal humeral 
bone cysts, in the transition between metaphyseal and diaphyseal bone, makes trabecular bone loss difficult to 
assess, due to a thick cortical background.
Findings of characteristic radiological changes inside the bone cavity, due to material resorption, are shared 
by many studies evaluating this product10–12. This is likely due to resorption of the calcium-sulphate component, 
because pure calcium-sulphate-based products are known to undergo rapid resorption13,14. Although partial 
resorption of CERAMENT is intended, to allow room for bone ingrowth, the rate of resorption could, unintend-
edly, have contributed to a higher number of re-operations in our study. We observed 10 re-operations: 5 within 
the first year and 5 in the second year. Product resorption did not influence the indication for re-operation in the 
4 patients having a local recurrence, in tumor-entities with a knowingly high local recurrence rate15,16; nor in the 
2 patients, where CERAMENT was re-injected. However, in the remaining 4 patients, the pattern of resorption 
of this product could have been a contributing factor in the decision to perform a re-operation. Firstly, it can be 
difficult to distinguish between the natural pattern of resorption and resorption due to disease progression. This 
uncertainty might have contributed to re-operation of two patients were primary operation had failed to give a 
specific diagnose. Secondly, the rate of product-resorption extinguished the hope of restoring normal trabecular 
bone throughout the cavity in two patients. And this was a central factor in the decision to make a re-operation, 
although cortical thickness was sufficient to permit full weight bearing (Fig. 2).
Beside a fast rate of resorption, calcium sulphate-containing bone graft substitutes are known to cause pro-
longed wound secretion13,17. Our typical wound closure technique, including intradermal suture and a skin glue, 
might explain why we only observed prolonged wound secretion in one patient. The inflammatory reaction seen 
in our cohort has previously been described in a study evaluating the same bone-graft substitute for defect-filling 
in hand-surgery12. The anatomical region might be a factor to determine which patients develop this inflam-
mation, because it has only been described in areas with little soft-tissue coverage, i.e. the knee, foot and hand. 
Although the inflammation seems benign and only causes temporary symptoms, it can lead to excessive use 
of antibiotics, when symptoms are presented to doctors not familiar with this phenomenon. In the previously 
mentioned study by Kaczmarczyk et al., no such complications were encountered10. The percutaneous technique 
used in their study could explain the low complication rate, possibly due to a low amount of product leakage into 
the soft-tissue. Considering that none of the patients in our study developed a deep infection, the inflammatory 
reaction is most likely aseptic. However, the absence of infections could also have been influenced by the local 
antibiotic delivery by the BGS.
The main limitations of our study are, firstly, the lack of 3-dimensional quantifications of bone formation. But 
due to ethical restrictions, repeated CT scans could not be performed in this study. However, cortical thickness 
is one of the parameters, which can be reliably evaluated in conventional x-rays, due to the high mineral den-
sity in cortical bone. Conversely, we could not reliably quantify the formation of new trabecular bone, but only 
describe the radiological appearance of the defect cavity. Secondly, this study is observational without any control 
group, which makes it impossible to distinguish between the effect of natural bone formation and the effect of the 
bone-graft substitute. However, we do get an indication of an actual effect of the bone-graft substitute in one case, 
where a patient with a bi-cameral bone-cyst acted as her own control group. One of the chambers, not receiving 
any filling, did not show any signs of healing, while the other chamber showed a good response to treatment 
(Fig. 1, upper row).
In conclusion, cortical thickness most commonly normalizes after bone tumor removal and filling of the bone 
defect using this particular composite ceramic bone graft substitute. The ceramic material undergoes resorption, 
which causes progressive changes in the radiological appearance inside the bone defect. This radiological behav-
ior should be kept in mind to ensure alignment of pre-operative expectations and the surgical result. Soft-tissue 
inflammation is a complication to the use of this bone graft substitute, but the reaction seems to be self-limiting. 
Otherwise, the use of this product has a low complication-rate.
Materials and Methods
Study Design. We performed a prospective study of all consecutive patients, who received bone-defect filling 
using two variants of the same composite ceramic bone graft substitute (CERAMENT|BONE VOID FILLER or 
CERAMENT|G, BONESUPPORT, SWEDEN) in the treatment of benign or borderline bone-tumors and cysts, 
in our orthopedic oncology department between August 1st 2014 and March 1st 2016. During this period, the 
bone graft substitute was first choice for bone-defect filling. All relevant data (age, gender, histological diagnosis, 
www.nature.com/scientificreports/
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grade, size and anatomical location of the lesion, details of the surgical procedure, use of orthopaedic implants, 
and occurrence of postoperative complications or local recurrence) were collected from the medical records, the 
national pathology database18, and the country-wide electronic patient file system. At the latest follow-up (May 
1st 2017) the minimum follow-up was 14 months (mean 22 (14–30) months).
Bone-Lesion Characteristics and Surgical Intervention. We calculated lesion-size by approximating 
measures from CT/MRI to a spherical shape (Height × Width × Length × 0.52)1. The cortical bone around the 
lesions was graded, with respect to radiological appearance, according to a modified Campanacci-classification, as 
intact (Grade 1), thinned (Grade 2), or breached by the tumor (Grade 3)19.
The indication for surgery was most often to obtain diagnosis (n = 23), and the remaining indications were: 
impending fracture (n = 4), progressive benign cyst (n = 4), and local recurrence (n = 4). Open curettage was 
performed in 31 cases, while an entirely percutaneous procedure was performed in 4 cases. CERAMENT|BONE 
VOID FILLER was used in the majority of cases (27 of 35), CERAMENT|G in 6 of 35 cases, and a combination 
of both in 2 of 35 cases. The mean amount of BGS used was 13 (2–56) mL. In 3 larger lesions, deemed struc-
turally impaired or at-risk of fracture, mechanical augmentation using plates was performed in addition to the 
bone-defect filling.
The composite ceramic bone-graft substitute. The two variants of the BGS have the same mineral 
composition and consist of 60% calcium-sulphate and 40% hydroxyapatite. Calcium-sulphate has a fast rate of 
resorption, typically within the first 6–12 weeks after the operation20,21. CERAMENT|BONE VOID FILLER con-
tains the contrast-agent, Iohexol, for enhanced radio-opacity. CERAMENT|G does not contain Iohexol, but con-
tains 175 mg of gentamicin per 10 mL paste22,23. Despite the mentioned differences, the two products are expected 
to have similar mechanical and degradation properties due to their similar mineral composition22,23.
Radiological evaluation. X-rays of the bone defects were evaluated by a specialist in radiology and two 
senior orthopedic surgeons. The post-operative x-rays were assessed for cortical thickness and the ratio of defect 
filling by the BGS. The x-rays taken one year after the operation were assessed for cortical thickness and the 
ratio of normal-appearing bone within the cavity (same opacity as surrounding bone). The pre-operative and 
1-year x-rays where compared for cortical thickness and cavity filling (Table 2). In the table showing the com-
parative radiological evaluation, the ratio of normal-appearing bone is referred to as cavity filling. In order to 
simplify the process of quantification, both cavity filling and cortical thickness were categorized into 4 groups: 
(1) >90% fill/thickness; (2) 50–90% fill/thickness; (3) 10–50% fill/thickness; and (4) <10% fill/thickness. The 
cortical-thickness-ratio was calculated by comparison to unaffected surrounding cortical bone.
In addition to the quantitative evaluation, x-rays taken after 1 year were classified according to a modified 
Neer’s classification of radiological bone-cyst appearance (Table 3)10,24. Patients, with/or suspected of local recur-
rence within 12 months of the primary operation, were classified as local recurrence in the modified Neer’s classi-
fication, although they did not achieve a full 12-months radiological follow-up, due to reoperations.
Study approval and informed consent. Study approval was obtained from the Danish Data Protection 
Agency (J.no. 2014-41-3021) and the Department of Health Agency. The study was performed in accordance with 
relevant guidelines and regulations. Written informed consent to participate in the study was obtained from the 
patients or their parents.
Data Availability
The authors do not have permission to share data from this study.
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